Entries by CTIC Team

Deep Genomics Shifts Focus to Genetic Medicines

By Allison Proffitt  May 12, 2017 | In August 2015 when Deep Genomics first launched, co-founder Brendan Frey made a prediction. “There’s a sea change coming,” he told Bio-IT World. “People are going to be focusing now on the machine learning component and trying to understand what the genome means, not just sequence a bunch […]

For some, access to healthcare could start with at-home lab testing

Most at-home lab testing devices like Scanadu and Cor are still waiting for FDA approval, but simple lab testing can still be done in the confines of your own home and then shipped to a lab and that’s led to a handful of new startups offering services like STD or food allergy tests. Everlywell, an […]

Tencent increases its focus on artificial intelligence

When it comes to artificial intelligence (AI) and Chinese tech companies, thoughts often begin and end with Baidu. But Tencent, Asia’s second highest-valued tech company behind Alibaba, has reminded the world that it too is investing in the field. Search giant Baidu was one of the first to make a major commitment to deep learning. […]

Uber’s autonomous test cars return to the road in San Francisco today

Uber has confirmed that its small fleet of autonomous vehicles in San Francisco will be back on the road today. The company grounded its entire self-driving test fleet in the U.S. on Saturday, following an accident involving one of its vehicles in Arizona earlier in the day. “We are resuming our development operations in San […]

Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal

NEW YORK (GenomeWeb) – Editas Medicine has signed a deal potentially worth more than $90 million, giving Allergan the exclusive rights to license certain of its CRISPR genome editing-based treatments for eye diseases. Under the terms of the deal, Allergan subsidiary Allergan Pharmaceuticals International Limited will have exclusive options to license up to five of […]

Freenome Raises $65M in Series A Funds

NEW YORK (GenomeWeb) – Palo Alto, California-based Freenome announced today that it has raised $65 million in Series A funding, which it will put toward conducting clinical trials to validate its non-invasive, early cancer detection technology. The round was led by venture capital firm Andreessen Horowitz, which last year helped the company raise $5.6 million […]

How the U.S. can beat hepatitis C: Don’t buy the pills, buy the company

Pharma veteran and MIT visiting scientist Mark Trusheim advances a provocative solution to overcome treatment costs.   In a recent article in Forbes, MIT Sloan School of Management visiting scientist Mark Trusheim and co-author Peter B. Bach, a physician at Memorial Sloan Kettering Cancer Center in New York, propose a startling response to the prevalence […]

New prospects for growing human replacement organs in animals

For the first time, biologists have succeeded in growing human stem cells in animal embryos, shifting from science fiction to the realm of the possible the idea of developing human organs in animals for later transplant. The approach involves generating stem cells from a patient’s skin, growing the desired new organ in a large animal, […]

Bloomberg: Chinese Investors Have Money, Want Biotech and Don’t Fear Trump

Despite tough talk by President-elect Donald Trump about a possible trade war, Chinese investors are hungry for U.S. biotech and they’ve got money to spend. In the latest purchase following a record 2016 for Chinese health-care takeovers, Nanjing-based Sanpower Group Co., said Tuesday it would buy a cancer treatment business from Valeant Pharmaceuticals International Inc. for […]

Digital Addiction Therapy Could Be First FDA-Approved App

LAS VEGAS — Digital therapy could soon be prescribed and reimbursed like a pharmaceutical drug for patients with chronic substance use disorder. “This could be a watershed moment for digital health,” said Corey McCann, MD, PhD, chief executive officer of Pear Therapeutics, the developer of the software. The product, known as reSET, is currently under […]